Stay updated with breaking news from David Ricks. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
US drug maker Eli Lilly plans to launch its weight-loss drugs Zepbound and Mounjaro in India next year. The company is considering pricing based on supply and volume expansion. Eli Lilly CEO David Ricks suggests focusing on digital services in the Indian healthcare industry to encourage innovation and improve access to healthcare.
At a market cap that exceeds $720 billion, US drug maker Eli Lilly tops the list of worlds most valuable pharmaceutical companies. The key to that is recent US approval for its weight-loss drug Zepbound (tirzepatide).
Eli Lilly's CEO David Ricks told Reuters on Wednesday that the U.S. drugmaker expects to launch its obesity drug in Indian market as early as next year.
HYDERABAD (Reuters) -U.S. drugmaker Eli Lilly expects to launch Mounjaro, its blockbuster diabetes drug and a wildly popular obesity treatment, in India as early as next year, CEO David Ricks told Reuters on Wednesday. The market opportunity is huge in the world's most populous country, which has high obesity rates, especially among women, and the second-highest number of people with type-2 diabetes globally. Indian drugmakers are making their own versions of such drugs, while illegal versions are also sold online.
Eli Lilly expects to launch its obesity drug tirzepatide in India as early as next year, the U.S. drugmaker's CEO David Ricks told Reuters on Wednesday. We're open to any way to reach...